AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

ITM expands PSMA-617 supply agreement for no-carrier-added Lutetium-177

March 2, 2020 GMT

GARCHING NEAR MUNICH, Germany--(BUSINESS WIRE)--Mar 2, 2020--

ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of companies announced today, that it has expanded a long-term agreement for the supply of highly pure no-carrier-added (n.c.a.) Lutetium-177 ( 177 Lu), which was originally concluded in 2018 between ITM AG and Endocyte, Inc., a Novartis company. Under the agreement, ITM will provide Endocyte with supply of n.c.a 177 Lu for its investigational 177 Lu-PSMA-617 radioligand therapy for patients with metastatic castration-resistant prostate cancer. Pending approval of investigational drug candidate 177 Lu-PSMA-617, ITM would continue to provide its proprietary n.c.a. 177 Lu during the commercial phase, supporting the scalability and security-of-supply for patients world-wide.

In addition, the parties have agreed that n.c.a. 177 Lu supplied by ITM will be used in future pipeline investigations.

Sidonie Golombowski-Daffner, President of Advanced Accelerator Applications, the radioligand business of Novartis, stated: “We believe in the potential of targeted radioligand therapy to transform the lives of patients and aspire to make it broadly available to those in need. This supply agreement supports our future growth and ability to investigate radioligand therapies in a variety of cancers.”

Steffen Schuster, CEO of ITM, commented: “We are very pleased to expand this long-term alliance, which allows us to further expand and support the development and increasing global patient access to targeted radioligand therapies. We are proud to contribute to these treatments by providing our highly pure n.c.a. 177 Lu. By 2030, therapeutic radiopharmaceuticals are expected to account for 50% of the nuclear medicine market. Thanks to the extension of the Endocyte supply agreement, we are confident that we can make a significant impact to this growing demand.”

- Ends -

View source version on businesswire.com:https://www.businesswire.com/news/home/20200302005435/en/

CONTACT: Nicola Scharrer

Head of Marketing & Communications

Phone: +49 89 3298986-151

Email:Nicola.Scharrer@itm.ag

KEYWORD: GERMANY EUROPE

INDUSTRY KEYWORD: RESEARCH GENETICS CLINICAL TRIALS BIOTECHNOLOGY RADIOLOGY HEALTH PHARMACEUTICAL SCIENCE ONCOLOGY

SOURCE: ITM

Copyright Business Wire 2020.

PUB: 03/02/2020 06:05 AM/DISC: 03/02/2020 06:05 AM

http://www.businesswire.com/news/home/20200302005435/en